Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer

被引：0
|
作者：
Musolino, A. [1 ]
Naldi, N. [1 ]
Bortesi, B. [1 ]
Capelletti, M. [1 ]
Pezzuolo, D. [1 ]
Michiara, M. [1 ]
Missale, G. [1 ]
Laccabue, D. [1 ]
Zerbini, A. [1 ]
Camisa, R. [1 ]
Ardizzoni, A. [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [41] Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
    Wang, Fuzhang
    Azim, Qurat-Ul-Ain
    Sohail, Ayesha
    Nutini, Alessandro
    Arif, Robia
    Tavares, Joao Manuel R. S.
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (01) : 123 - 131
  • [42] Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
    N Ady
    L Morat
    K Fizazi
    J-C Soria
    M-C Mathieu
    D Prapotnich
    L Sabatier
    L Chauveinc
    British Journal of Cancer, 2004, 90 : 443 - 448
  • [43] Serum HER-2/neu decline predicts improved response to trastuzumab-based therapy in patients with normal and elevated baseline serum HER-2/neu levels.
    Ali, S. M.
    Brault, D.
    Brown-Shimer, S.
    Carney, W.
    Esteva, F. J.
    Fornier, M.
    Gligorov, J.
    Hamer, P.
    Harris, L.
    Leitzel, K.
    Kostler, W.
    Lotz, J-P
    Luftner, D.
    Pichon, M-F
    Thiel, R. P.
    Tse, C.
    Wheler, J.
    Lipton, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S90 - S90
  • [44] Response prediction in neoadjuvant trastuzumab treated HER-2/neu-positive breast cancer by quantitative RT-PCR analysis of FFPE tissue.
    Rueckert, S.
    Wirtz, R. M.
    Lenhard, M.
    Ruehl, I
    Hasmueller, S.
    Ditsch, N.
    Bauerfeind, I
    Untch, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S138 - S138
  • [45] Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy
    Esteva, FJ
    Cheli, C
    Fritsche, HA
    Fornier, M
    Slamon, DJ
    Thiel, RP
    Luftner, D
    Ghani, F
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S220 - S220
  • [46] HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Konecny, GE
    Thomssen, C
    Lück, HJ
    Untch, M
    Wang, HJ
    Kuhn, W
    Eidtmann, H
    du Bois, A
    Olbricht, S
    Steinfeld, D
    Möbus, V
    von Minckwitz, G
    Dandekar, S
    Ramos, L
    Pauletti, G
    Pegram, MD
    Jänicke, F
    Slamon, DJ
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1141 - 1151
  • [47] Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?
    Skedgel, C.
    Rayson, D.
    Younis, T.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1834 - 1840
  • [48] HER-2/neu positive breast cancer:: how to prescribe adjuvant trastuzumab (Herceptin®)?
    Belkacemi, Yazid
    Gligorov, Joseph
    Mauriac, Louis
    Azria, David
    BULLETIN DU CANCER, 2006, 93 (10) : 991 - 999
  • [49] Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer
    Ozyukseler, Deniz Tataroglu
    Basak, Mustafa
    Ay, Seval
    Koseoglu, Aygul
    Arici, Serdar
    Oyman, Abdilkerim
    Surmeli, Heves
    Turan, Merve
    Turan, Nedim
    Odabas, Hatice
    Yildirim, Mahmut E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 547 - 554
  • [50] Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer
    Lanza-Jacoby, Susan
    Burd, Randy
    Rosato, Francis E., Jr.
    McGuire, Kandace
    Little, James
    Nougbilly, Noel
    Miller, Sheldon
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6161 - 6169
12345